// App-Quantinova.ai

505 : Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

Researchers

Presenter

  • Jennifer Keating Litton

Principal Investigators

  • Joseph Thaddeus Beck

  • Jason M. Jones

  • Jay Andersen

  • Joanne Lorraine Blum

  • Lida A. Mina

  • Raymond Brig

  • Michael A. Danso

  • Yuan Yuan

  • Antonello Abbattista

  • Kay Noonan

  • Jayeta Chakrabarti

  • Akos Czibere

  • William Fraser Symmans

  • Melinda L. Telli

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Highlands Oncology Group, Springdale, AR

  • Avera Cancer Institute, Sioux Falls, SD

  • Compass Oncology, West Cancer Center, Tigard, OR

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center and The US Oncology Network, Dallas, TX

  • Banner MD Anderson Cancer Center, Mesa, AZ

  • Brig Center for Cancer Care and Survivorship, Knoxville, TN

  • Virginia Oncology Associates, Norfolk, VA

  • City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA

  • Pfizer Inc, Milan, Italy

  • Pfizer, Groton, CT

  • Pfizer Inc., Walton Oaks, United Kingdom

  • Pfizer Inc., Cambridge, MA

  • Stanford School of Medicine, Stanford, CA

Locations

  • United States

  • Italy

  • United Kingdom

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Renal insufficiency

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Talazoparib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT03499353

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved